Melasma
Conditions
Interventions
Test Group:After the subject was anesthetized, one tube of Bole Da 30% supramolecular salicylic acid (7g/tube) was first applied for five minutes (no dilution required and fully absorbed). Then, gold
Control group:Subjects received only gold radiofrequency microneedling treatment after anesthesia.
Sponsors
Nanjing Yijia Aesthetic Clinic
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Female subjects aged 25-60 years (must distinguish between premenopausal and postmenopausal subjects); 2. Only subjects with stable melasma shall be included, ensuring no other skin discomfort symptoms; 3. Light brown to dark brown, well-defined patches on the face with symmetrical distribution; 4. No inflammation, scaling, or significant discomfort symptoms on the skin; 5. Facial pigmentation appearing after adulthood; 6. Subjects voluntarily participate and must sign informed consent forms.
Exclusion criteria
Exclusion criteria: 1. Individuals known to be allergic to the test drug or with hypersensitive constitution; 2. Pregnant, planning to become pregnant, or lactating women; 3. Individuals who have received facial photoelectric treatments, injections (including hyaluronic acid injections), or surgical treatments within two months prior to the trial; 4. Individuals who have orally taken medications or supplements with skin-whitening effects in the past month, such as retinoic acid, lycopene, tranexamic acid, or used other topical whitening products; 5. Individuals who work outdoors for more than two hours daily, have sunburns, or inadequate sun protection; 6. Individuals with facial pigmentation caused by acquired bilateral nevus of Ota-like macules on the malar region, Riehl's melanosis, pigmented actinic lichen planus, or melasma caused by hormones or cosmetics; 7. Individuals with unstable emotions, sensitive skin, or excessively high expectations for the trial outcomes who may be uncooperative during follow-up; 8. Individuals with photosensitive skin diseases, systemic lupus erythematosus (SLE), dermatomyositis, scleroderma, or rheumatoid arthritis; 9. Individuals with a scar-prone constitution or needle phobia, who are unwilling to accept the treatment method of this study; 10. Individuals taking oral contraceptives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total effective rate at the end of week 18; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improved mMASI rating;Red area assessment before and after treatment; | — |
Countries
China
Contacts
Public ContactZhonglan Pan
Nanjing Yijia Medical Cosmetology Clinic
Outcome results
None listed